Okay, I'm Viraj Mithani from Jupiter Financial. Am I audible?
Okay, good evening, sir, and thank you for the opportunity. Sir, my first question is the recent acquisition by the Glaxo parent, how is it going to benefit India and in what time frame will it benefit India? The biopharma and some two-three acquisitions have happened recently?
Yeah. My name is Viraj Mithani and I am from Jupiter Financial. Sorry, I joined the call late. This oncological revenue will start coming from this quarter or when will the revenue start keeping on the oncological drug?
And any new more products to be introduced in this year?
My question is in terms of the launches…
So, my question is , there are two launches. One is in the oncological segment, which you said and one is in the respiratory. So, can you give some color in terms of the profitability, growth profile and the profitability of the company? Would it change the margins and any color is useful for us? I know you don't give guidance, but you can at least give some color. That's my first question.
My question is answered.
Good afternoon and congratulations for the good set of numbe rs most of my question are answered. You talked about all this new segment, this airport, e-mobility does it mean we are shifting from more products to solution based company that is why the transition ing happening there and also would it mean that our mar gins in days to come would be much higher because if you can give some opportunity size on all the segments you talked about emerging market, green growth, mobility it will be helpful.
So, we are becoming more solution -based company. We are probably moving towards a higher trajectory margin side that is what is the attempt is it correct to think that way.